Clinical trials: Prostaglandins
Type 2 Diabetes Mellitus
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a specific metabolite (which is a marker of in vivo…
- Trial name
- NCT00618995
- Testing
- Comparator: ER niacin (+) laropiprant, Comparator: ER niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection.
- Trial name
- NCT05706454
- Testing
- Ramatroban
- Where
- 7 sites in India
- Volunteers
- 324 people
- Sponsor
- KARE Biosciences
Macular Degeneration
Alprostadil in Maculopathy Study (AIMS)
Evaluation of efficacy of alprostadil (prostaglandin E1) for treatment of patients suffering from dry age-related macula degeneration
- Trial name
- NCT00619229
- Testing
- Alprostadil (prostaglandin E1)
- Where
- 6 sites in Germany
- Volunteers
- 37 people
- Sponsor
- UCB Pharma
Normal Tension Glaucoma, Primary Open-angle Glaucoma
Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl
This study is for patients have been using prostaglandin analogue eye drops with a preservative for 3 months or more and have been diagnosed with prostaglandin-associated peri-orbital disease.
- Conditions
- Normal Tension Glaucoma, Primary Open-angle Glaucoma, Glaucoma, Suspect, Ocular Hypertension
- Trial name
- NOPAPS (NCT05279716)
- Testing
- Eybelis ophthalmic solution 0.002%
- Where
- 8 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- Santen Pharmaceutical Asia Pte. Ltd.
Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
This trial is a prospective, open-label, single-arm trial of the safety of a single FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity conditioning regimen for hematologic malignancies.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease, Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML)
- Trial name
- NCT01527838
- Testing
- Single FT1050 treated UCB unit
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Fate Therapeutics
Ocular Hypertension, Open Angle Glaucoma
Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®
The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin…
- Trial name
- NCT01937299
- Testing
- Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, Travoprost 0.004% ophthalmic solution
- Volunteers
- 307 people
- Sponsor
- Alcon Research
Stage II Peripheral Arterial Occlusive Disease, Intermittent Claudication Fontaine Stage II PAOD
Prostaglandin E1 in Outpatients With Intermittent Claudication
Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with…
- Trial name
- NCT01263925
- Testing
- Alprostadil (Prostaglandin E1), Pentoxifylline
- Where
- 36 sites in Germany
- Volunteers
- 561 people
- Sponsor
- UCB Pharma
Ocular Hypertension, Open Angle Glaucoma
Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue
The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin…
- Trial name
- NCT01937312
- Testing
- Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, Prostaglandin analogue
- Volunteers
- 282 people
- Sponsor
- Alcon Research
Inflammation
Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
- Trial name
- NCT00791323
- Testing
- Ketorolac 0.4%, Lubricating Eye Drop
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.
Open Angle Glaucoma, Ocular Hypertension
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues
- Trial name
- NCT00539526
- Testing
- Bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005% eye drops
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Allergan
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Pulmonary Arterial Hypertension
This is a prospective, multi-center, open-label, randomized, Phase IV exploratory study comparing safety, tolerability, pharmacokinetics, and effectiveness of ACT-385781A and Flolan (epoprostenol sodium) in patients with…
- Trial name
- EPITOME-1 (NCT01105091)
- Testing
- ACT-385781A (Actelion Epoprostenol), Flolan®
- Volunteers
- 30 people
- Sponsor
- Actelion